A5084303748- BRCA gene mutations in cancer
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Cancer Risks and Factors
- Molecular Biology Techniques and Applications
- CRISPR and Genetic Engineering
- Nutrition, Genetics, and Disease
- Genetics, Bioinformatics, and Biomedical Research
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- Bone health and treatments
- Metabolism, Diabetes, and Cancer
- Breast Lesions and Carcinomas
- Cancer Immunotherapy and Biomarkers
- Ovarian cancer diagnosis and treatment
- Genetic factors in colorectal cancer
- Genetic Associations and Epidemiology
- Radiopharmaceutical Chemistry and Applications
- Breast Implant and Reconstruction
- Adipokines, Inflammation, and Metabolic Diseases
- Metastasis and carcinoma case studies
Comprehensive Cancer Center Vienna
2016-2025
Medical University of Vienna
2016-2025
Austrian Breast & Colorectal Cancer Study Group
2011-2025
Vienna General Hospital
2019
Medical University of Graz
2010-2018
LKH Hochsteiermark
2017-2018
Ordensklinikum Linz Barmherzige Schwestern
2018
Paracelsus Medical University
2017-2018
Klinik Hietzing
2017
University of Cambridge
2017
Background. Immunomagnetic EpCAM based methods are used to enrich circulating tumor cells (CTCs) in metastatic breast cancer (mBC) patients. negative CTCs may be missed. We addressed the question of reliability an dependent assay CTCs. Methods. To elucidate this issue, our study has been designed assess two different CTC enrichment technologies (i) positive (+) and cell lines (ii) mBC patients dependency on their respective expression. These encompass one anti-EpCAM immunomagnetic...
Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, potential value of adding palbociclib to endocrine therapy hormone receptor-positive cancer has not been confirmed.
Brain metastases (BM) are a devastating complication of HER2-positive metastatic breast cancer (BC) and treatment strategies providing optimized local systemic disease control urgently required. The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) improved progression-free survival (PFS) overall (OS) over emtansine but data regarding intracranial activity is limited. In the primary outcome analysis TUXEDO-1, high response rate (RR) was reported with T-DXd. Here, we report final PFS OS results.
Aromatase inhibitors are effective as endocrine treatment for patients with hormone receptor-positive breast cancer. According to the hypothesis that overweight have higher levels of aromatase enzyme availability, we investigated influence body mass index (BMI) on efficacy adjuvant therapy in premenopausal a retrospective analysis Austrian Breast and Colorectal Cancer Study Group (ABCSG) 12 trial.ABCSG-12 examined ovarian suppression using goserelin (3.6 mg subcutaneously every 28 days)...
Breast cancer is the most common female cancer, affecting approximately one in eight women during their life-time. Besides environmental triggers and hormones, inherited mutations breast 1 (BRCA1) or BRCA2 genes markedly increase risk for development of cancer. Here, using two different mouse models, we show that genetic inactivation key osteoclast differentiation factor RANK mammary epithelium delayed onset, reduced incidence, attenuated progression Brca1;p53 mutation-driven Long-term...
Common genetic variants contribute to the observed variation in breast cancer risk for BRCA2 mutation carriers; those known date have all been found through population-based genome-wide association studies (GWAS). To comprehensively identify modifying loci carriers, we conducted a deep replication of an ongoing GWAS discovery study. Using ranked P-values associations with imputed genotype 1.4 M SNPs, 19,029 SNPs were selected and designed inclusion on custom Illumina array that included...
BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of or weight. This preplanned analysis the global randomized PALLAS trial investigates impact on side-effect profile, treatment adherence, efficacy palbociclib.
Abstract Background: The fasting serum lipid profile [triglycerides (TGs), total cholesterol (TC), and LDL- HDL-cholesterol (LDL-C HDL-C)] is used to calculate ratios (TC/HDL-C, LDL-C/HDL-C, TG/HDL-C) that allow identification of individuals at increased risk for cardiovascular disease. Because these are also frequently insulin resistant, this study analyzed the relationships between sensitivity. Methods: In 132 obese [mean (SE) body mass index, 37.5 (0.6) kg/m2] outpatients without known...
Accurate response assessment during neoadjuvant systemic treatment (NST) poses a clinical challenge. Therefore, minimally invasive of tumor based on cell-free circulating DNA (ctDNA) may be beneficial to guide decisions.
Estrogen receptor (ER) beta1 and its splice variants are expressed both in ovary ovarian cancer. We studied the role of ERbeta1 two regulation gene expression, cellular proliferation, apoptosis, migration an cancer cell line. In this study, we transfected SK-OV-3 cells with vectors coding for or ERbeta-delta125 ERbeta-delta1256, tested their response to estrogen tamoxifen comparison untransfected cells. Heterologous expression ERbeta1, but not exon-deleted ERbeta resulted notably slower...
We investigated whether body mass index (BMI) can be used as a predictive parameter indicating patients who benefit from extended aromatase inhibitor (AI) treatment. The ABCSG-6a trial re-randomised event-free postmenopausal hormone receptor-positive the ABCSG-6 to receive either 3 additional years of endocrine therapy using anastrozole vs nil. In this retrospective analysis, we prognostic and impact BMI on disease outcome safety. all, 634 (177 normal weight, 307 overweight, 150 obese) were...
Background Gamma-glutamyltransferase (GGT) is a known marker for apoptotic balance and cell detoxification. Recently, an association of baseline GGT levels breast cancer incidence, tumor progression chemotherapy resistance was shown. The purpose this study to evaluate the pre-therapeutic levels, clinical-pathological parameters survival in patients with primary metastatic (PMBC). Methods In multicenter analysis, 114 diagnosed PMBC between 1996 2012 were evaluated. analysed. Patients...
The purpose of this study was to evaluate socio-demographic characteristics clients claiming genetic counseling for hereditary breast and ovarian cancer (HBOC) in Austria. Furthermore, changes these parameters before after Angelina Jolie's (AJ) disclosure carrying a BRCA mutation were evaluated. In prospective, nonrandomized 268 consecutive seeking HBOC at the Medical University Vienna, Department Obstetrics Gynecology, Austria between June 2012 2014 included. Socio-demographic data source...
BACKGROUND: Adjuvant aromatase inhibitors increase osteoporosis and fractures in patients with hormone receptor–positive breast cancer. We have previously reported outcomes of the ABCSG-18 (study 18 from Austrian Breast & Colorectal Cancer Study Group) trial showing that adjuvant anti–receptor activator nuclear factor-κB ligand denosumab treatment counteracts these adverse effects may improve outcomes. report here final long-term METHODS: is a prospective, double-blind, placebo-controlled,...
Brain metastases (BM) are a common site of progression in TNBC increasing morbidity and mortality. Strategies providing both intra- extracranial disease control urgently required. Dato-DXd is Trop2-directed antibody-drug conjugate (ADC) with activity TNBC. Here we report results the first stage prospective single-arm phase II TUXEDO-2 trial investigating safety pts active BM. includes adult newly diagnosed untreated or progressing BM no indication for immediate local treatment. administered...
Concomitant intake of proton pump inhibitors (PPIs) may create drug-drug interactions, potentially impacting efficacy anticancer agents. In the phase III PALLAS trial, addition palbociclib capsules to standard adjuvant endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer did not improve invasive disease-free survival (iDFS). We explored whether concomitant use PPIs affected outcomes treated PALLAS.
Objective Aromatase inhibitors are essential as endocrine treatment for hormone receptor-positive postmenopausal breast cancer patients. Menopausal symptoms often aggravated during treatment. We investigated whether vaginal estriol is a safe therapeutic option to overcome the urogenital side-effects of aromatase inhibitors. Serum levels were used surrogate parameter safety.Methods Fasting serum ten patients receiving prospectively measured by electro-chemiluminescence immunoassays and gas...
Body mass index (BMI) has an impact on survival outcome in patients treated with aromatase inhibitors (AIs). Obesity is associated increased body aromatisation and may be a cause of insufficient estradiol depletion. Sixty-eight postmenopausal oestrogen receptor-positive early breast cancer were prospectively included this study. Follicle stimulating hormone (FSH), luteinizing (LH) analysed immediately the clinical routine lab dedicated central before (T1) 3 months after start (T2). A total...